Literature DB >> 12271800

Improvement in cognitive functioning in patients with first-episode psychosis during treatment with quetiapine: an interim analysis.

K P Good1, I Kiss, C Buiteman, H Woodley, Q Rui, D Whitehorn, L Kopala.   

Abstract

BACKGROUND: The efficacies of second-generation antipsychotic medications in reducing symptoms are reasonably well-documented, but their effects on cognition are less clearly understood. AIMS: To under take an interim analysis of an open label, 2-year study examining the effects of quetiapine on cognition in patients with a first episode of schizophrenia and related disorders.
METHOD: Cognitive testing was performed before quetiapine was initiated and repeated after 3, 6 and 12 months of treatment. To date, 13 patients have been fully assessed (mean dose 517.9 mg/day; s.d. = 225.8).
RESULTS: Statistically significant improvement was noted on measures of attention (Continuous Performance Test; CPT), verbal productivity (Verbal Fluency Test) and executive function (Object Alternation Test) after 6 and 12 months of treatment. For the CPT, improvement was also noted after 3 months of treatment.
CONCLUSIONS: During treatment for 1 year with quetiapine, cognitive performance was improved in young patients with psychosis. Continued controlled investigations of the effects of quetiapine on cognition are desirable.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12271800     DOI: 10.1192/bjp.181.43.s45

Source DB:  PubMed          Journal:  Br J Psychiatry Suppl        ISSN: 0960-5371


  10 in total

1.  Cognitive efficacy of quetiapine in early-onset first-episode psychosis: a 12-week open label trial.

Authors:  Sébastien Urben; Pierre Baumann; Sandra Barcellona; Muriel Hafil; Ulrich Preuss; Claire Peter-Favre; Stéphanie Clarke; Olivier Halfon; Laurent Holzer
Journal:  Psychiatr Q       Date:  2012-09

Review 2.  First-episode schizophrenia: a focus on pharmacological treatment and safety considerations.

Authors:  Deanna L Kelly; Robert R Conley; William T Carpenter
Journal:  Drugs       Date:  2005       Impact factor: 9.546

3.  Sustained attention deficits among HIV-positive individuals with comorbid bipolar disorder.

Authors:  Carolina Posada; David J Moore; Reena Deutsch; Alexandra Rooney; Ben Gouaux; Scott Letendre; Igor Grant; J Hampton Atkinson
Journal:  J Neuropsychiatry Clin Neurosci       Date:  2012       Impact factor: 2.198

4.  Effects of treatment with the atypical neuroleptic quetiapine on working memory function: a functional MRI follow-up investigation.

Authors:  E M Meisenzahl; J Scheuerecker; M Zipse; S Ufer; M Wiesmann; T Frodl; N Koutsouleris; T Zetzsche; G Schmitt; M Riedel; I Spellmann; S Dehning; J Linn; H Brückmann; H J Möller
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2006-12-06       Impact factor: 5.270

Review 5.  Quetiapine. A review of its use in the management of schizophrenia.

Authors:  Susan M Cheer; Antona J Wagstaff
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

6.  Efficacy of olanzapine versus quetiapine on cognitive dysfunctions in patients with an acute episode of schizophrenia.

Authors:  Michael Riedel; Norbert Müller; Ilja Spellmann; Rolf R Engel; Richard Musil; Rosamaria Valdevit; Sandra Dehning; Anette Douhet; Anja Cerovecki; Martin Strassnig; Hans-Jürgen Möller
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2007-10       Impact factor: 5.270

7.  Effects of quetiapine and sertindole on subchronic ketamine-induced deficits in attentional set-shifting in rats.

Authors:  Agnieszka Nikiforuk; Piotr Popik
Journal:  Psychopharmacology (Berl)       Date:  2011-09-15       Impact factor: 4.530

8.  Quetiapine in the treatment of schizophrenia and related disorders.

Authors:  Michael Riedel; Norbert Müller; Martin Strassnig; Ilja Spellmann; Emanuel Severus; Hans-Jürgen Möller
Journal:  Neuropsychiatr Dis Treat       Date:  2007-04       Impact factor: 2.570

9.  Data Gathering Bias: Trait Vulnerability to Psychotic Symptoms?

Authors:  Ana Catalan; Claudia J P Simons; Sonia Bustamante; Nora Olazabal; Eduardo Ruiz; Maider Gonzalez de Artaza; Alberto Penas; Claudio Maruottolo; Claudio Maurottolo; Andrea González; Jim van Os; Miguel Angel Gonzalez-Torres
Journal:  PLoS One       Date:  2015-07-06       Impact factor: 3.240

10.  Paliperidone Compared with Haloperidol on the Theory of Mind Tasks in Schizophrenia: A Pilot Trial.

Authors:  Jie Zhong; Hong Zhu; Dongqing Yin; Yanzhe Ning; Sisi Zheng; Yanbo Zhang; Hongxiao Jia
Journal:  Neuropsychiatr Dis Treat       Date:  2021-12-14       Impact factor: 2.570

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.